BACKGROUND: De novo use of mammalian target of rapamycin inhibitors after kidney transplantation is associated with a concentration-dependent incidence of wound healing adverse events (WHAE). The objective of this analysis was to compare the incidence of WHAE in patients receiving everolimus (EVR) ormycophenolate sodium (MPS). METHODS: This was a predefined subanalysis of a single-center prospective randomized study in which 288 kidney transplant recipients receivingtacrolimus and prednisone were randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab (BAS)/EVR (N = 102); BAS/MPS (N = 101). Clinical WHAE were prospectively collected using a prespecified case report form in all study visits. Abdominal ultrasound was performed at 30 days posttransplant to capture subclinical abnormalities. Surgeons were blinded to randomized treatment and no specific surgical procedures were implemented. RESULTS: A higher proportion of patients in BAS/EVR showed at least 1 clinical WHAE (22.3% vs 35.3% vs 22.0%, P = 0.03) and total clinical and subclinical WHAE (35% vs 42% vs 26%, P = 0.014) compared with BAS/MPS, respectively. A higher proportion of patients in r-ATG/EVR showed subclinical WHAE (13% vs 7% vs 4%, P = 0.025) compared with BAS/MPS, respectively. Patients receiving EVR showed a higher risk of developing clinical or subclinical WHAE (r-ATG/EVR vs BAS/MPS hazard ratio 1.30; BAS/EVR vs BAS/MPS hazard ratio 1.73, P = 0.028). CONCLUSIONS: In this cohort of de novo kidney transplant recipients receivingtacrolimus and prednisone, the use of EVR was associated with higher incidence of combined clinical and subclinical WHAE compared with MPS.
RCT Entities:
BACKGROUND: De novo use of mammalian target of rapamycin inhibitors after kidney transplantation is associated with a concentration-dependent incidence of wound healing adverse events (WHAE). The objective of this analysis was to compare the incidence of WHAE in patients receiving everolimus (EVR) or mycophenolate sodium (MPS). METHODS: This was a predefined subanalysis of a single-center prospective randomized study in which 288 kidney transplant recipients receiving tacrolimus and prednisone were randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab (BAS)/EVR (N = 102); BAS/MPS (N = 101). Clinical WHAE were prospectively collected using a prespecified case report form in all study visits. Abdominal ultrasound was performed at 30 days posttransplant to capture subclinical abnormalities. Surgeons were blinded to randomized treatment and no specific surgical procedures were implemented. RESULTS: A higher proportion of patients in BAS/EVR showed at least 1 clinical WHAE (22.3% vs 35.3% vs 22.0%, P = 0.03) and total clinical and subclinical WHAE (35% vs 42% vs 26%, P = 0.014) compared with BAS/MPS, respectively. A higher proportion of patients in r-ATG/EVR showed subclinical WHAE (13% vs 7% vs 4%, P = 0.025) compared with BAS/MPS, respectively. Patients receiving EVR showed a higher risk of developing clinical or subclinical WHAE (r-ATG/EVR vs BAS/MPS hazard ratio 1.30; BAS/EVR vs BAS/MPS hazard ratio 1.73, P = 0.028). CONCLUSIONS: In this cohort of de novo kidney transplant recipients receiving tacrolimus and prednisone, the use of EVR was associated with higher incidence of combined clinical and subclinical WHAE compared with MPS.
Authors: Matthew R Weir; Shamkant Mulgaonkar; Laurence Chan; Hamid Shidban; Thomas H Waid; Dennis Preston; Roberto N Kalil; Thomas C Pearson Journal: Kidney Int Date: 2010-12-29 Impact factor: 10.612
Authors: C C Rogers; M Hanaway; R R Alloway; J W Alexander; R E Boardman; J Trofe; M Gupta; T Merchen; J F Buell; M Cardi; P Roy-Chaudhury; P Succop; E S Woodle Journal: Transplant Proc Date: 2005-03 Impact factor: 1.066
Authors: B Sis; M Mengel; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; W M Baldwin; E R Bracamonte; V Broecker; F Cosio; A J Demetris; C Drachenberg; G Einecke; J Gloor; D Glotz; E Kraus; C Legendre; H Liapis; R B Mannon; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; E R Rodriguez; D Seron; S Seshan; M Suthanthiran; B A Wasowska; A Zachary; A Zeevi Journal: Am J Transplant Date: 2010-01-29 Impact factor: 8.086
Authors: Stuart M Flechner; Lingmei Zhou; Ithaar Derweesh; Barbara Mastroianni; Kathy Savas; David Goldfarb; Charles S Modlin; Venkatesh Krishnamurthi; Andrew Novick Journal: Transplantation Date: 2003-12-27 Impact factor: 4.939
Authors: Mahesh Goel; Stuart M Flechner; Lingme Zhou; Barbara Mastroianni; Kathy Savas; Ithaar Derweesh; Pratik Patel; Charles Modlin; David Goldfarb; Andrew C Novick Journal: J Urol Date: 2004-05 Impact factor: 7.450
Authors: Richard J Knight; Martin Villa; Robert Laskey; Carlos Benavides; Linda Schoenberg; Maria Welsh; Ronald H Kerman; Hemangshu Podder; Charles T Van Buren; Stephen M Katz; Barry D Kahan Journal: Clin Transplant Date: 2007 Jul-Aug Impact factor: 2.863
Authors: Ho Yee Tiong; Stuart M Flechner; Lingme Zhou; Alvin Wee; Barbara Mastroianni; Kathy Savas; David Goldfarb; Ithaar Derweesh; Charles Modlin Journal: Transplantation Date: 2009-01-27 Impact factor: 4.939
Authors: Sandra R DiBrito; Israel O Olorundare; Courtenay M Holscher; Claudia S Landazabal; Babak J Orandi; Nabil N Dagher; Dorry L Segev; Jacqueline Garonzik-Wang Journal: Clin Transplant Date: 2018-04-17 Impact factor: 2.863
Authors: Daniel Fantus; Helong Dai; Yoshihiro Ono; Alicia Watson; Shinichiro Yokota; Kanishka Mohib; Osamu Yoshida; Mark A Ross; Simon C Watkins; Bala Ramaswami; Anna Valusjkikh; David M Rothstein; Angus W Thomson Journal: Transplantation Date: 2017-12 Impact factor: 4.939
Authors: Deirdre Hahn; Elisabeth M Hodson; Lorraine A Hamiwka; Vincent Ws Lee; Jeremy R Chapman; Jonathan C Craig; Angela C Webster Journal: Cochrane Database Syst Rev Date: 2019-12-16
Authors: Muhammad Abdul Mabood Khalil; Saeed M G Al-Ghamdi; Ubaidullah Shaik Dawood; Said Sayed Ahmed Khamis; Hideki Ishida; Vui Heng Chong; Jackson Tan Journal: J Transplant Date: 2022-02-28